射血分数降低心衰四联疗法的费用抵消分析
模型预测四联GDMT可显著减少住院相关支出,多数方案在计入药物成本后实现净节省。
要点
- 模型预测四联GDMT使心衰住院相对降低87%、全因住院降低61%。
- 四联GDMT较部分GDMT预计年减少住院支出9780美元,多数方案净节省。
核心结论
- 在HFrEF住院老年患者中,实施四联GDMT可显著降低住院相关费用,计入药物成本后多数方案实现净节省。
主要发现
- 模型预测四联GDMT与心衰住院相对降低87%(95% CI,81%-91%)相关,与全因住院相对降低61%(95% CI,51%-68%)相关。
临床怎么用
- 对于HFrEF住院患者,出院时启动或优化四联GDMT不仅改善预后,从支付方视角看多数方案可抵消药物成本。
局限性
- 研究为基于注册登记和 Medicare 支付数据的模型预测,非随机对照试验直接观察的成本效果分析。
- 治疗效应来自关键RCT的外推,药物成本来自多个定价来源,实际净节省可能因价格和人群差异而不同。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Contemporary guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF), which includes angiotensin receptor-neprilysin inhibitors (ARNI), β-blockers, mineralocorticoid receptor antagonists (MRAs), and sodium-glucose cotransporter 2 inhibitors (SGLT2i), reduces hospitalizations in randomized clinical trials (RCTs), but the combined economic impact of implementing full quadruple therapy after hospitalization is not well quantified. OBJECTIVE: To estimate the 1-year health care cost offset and net cost associated with implementation of quadruple GDMT after hospitalization for HFrEF. DESIGN, SETTING, AND PARTICIPANTS: This economic evaluation used Medicare-linked data from the American Heart Association's Get With The Guidelines-Heart Failure (GWTG-HF) registry to identify adults 65 years or older hospitalized with HFrEF from 2016 to 2020 with up to 1-year postdischarge follow-up. Data were analyzed from November 2025 to February 2026. EXPOSURES: Receipt of quadruple GDMT, defined as concurrent use of an ARNI, β-blocker, MRA, and SGLT2i, at hospital discharge and modeled according to class-specific eligibility and treatment effect estimates from pivotal RCTs. MAIN OUTCOMES AND MEASURES: Mean per-patient total health care costs through 1 year after discharge were calculated using Medicare Parts A and B payments. Treatment effect estimates for ARNI, β-blockers, MRAs, and SGLT2i were derived from pivotal RCTs and combined multiplicatively on the log scale, incorporating class-specific eligibility, to estimate projected reductions in hospitalization-associated expenditures. Net annual cost was calculated by integrating drug acquisition costs across multiple pricing sources with predicted hospitalization cost reductions. RESULTS: The cohort included 50 598 older adults hospitalized with HFrEF (median [IQR] age, 78 [72-85] years; 31 268 men [61.8%] and 19 330 women [38.2%]). Mean 1-year total health care costs were $41 802 per patient, with $25 172 attributable to all-cause hospitalizations. Modeled quadruple GDMT was associated with an 87% (95% CI, 81%-91%) relative reduction in HF hospitalizations and a 61% (95% CI, 51%-68%) reduction in all-cause hospitalizations. Full quadruple therapy implementation vs partial GDMT was projected to reduce hospitalization-associated expenditures by $9780 (95% CI, $7900-$11 660) per patient annually. With annual drug costs ranging from $1223 to $16 136, the resulting net annual cost ranged from $8556 in savings to $6347 in net cost, with most regimens yielding net savings. CONCLUSIONS AND RELEVANCE: Among US adults hospitalized with HFrEF, 1-year health care costs are substantial and driven predominantly by hospitalizations. Using combined trial effects and real-world Medicare data, this study found that implementation of quadruple GDMT would meaningfully reduce hospitalization-associated costs and often yield net savings after accounting for medication expenses.
引用
- Keykhaei, Rashedi, Greene, et al. Cost Offset With Quadruple Therapy for Heart Failure. JAMA Cardiol. 2026. PMID: 42268625. doi:10.1001/jamacardio.2026.1552
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。